Prestige Consumer Healthcare ( (PBH) ) has shared an announcement.
On May 8, 2025, Prestige Consumer Healthcare reported record revenue and earnings for the fiscal year ending March 31, 2025, with a revenue of $1,137.8 million and a diluted EPS of $4.29. The company saw significant growth in its international business and North American categories, particularly in gastrointestinal and women’s health, and achieved a strong free cash flow, which facilitated share repurchases and debt reduction. Looking ahead to fiscal 2026, Prestige anticipates organic revenue growth of 1% to 2% and EPS growth, despite inflationary challenges, leveraging its diverse product portfolio and agile operating model to maintain consistent financial performance and shareholder value.
Spark’s Take on PBH Stock
According to Spark, TipRanks’ AI Analyst, PBH is a Neutral.
Prestige Consumer Healthcare’s strong profitability and cash flow, effective cost management, and debt reduction efforts are significant strengths. However, limited revenue growth and mixed technical indicators present challenges. The stock’s valuation is reasonable, supporting a moderately positive outlook.
To see Spark’s full report on PBH stock, click here.
More about Prestige Consumer Healthcare
Prestige Consumer Healthcare Inc. operates in the healthcare industry, focusing on over-the-counter (OTC) healthcare products. The company offers a diverse portfolio of needs-based products, including brands like Summer’s Eve, Dramamine, Fleet, and Hydralyte, with a market focus on North America and international segments.
Average Trading Volume: 370,366
Technical Sentiment Signal: Buy
Current Market Cap: $4.01B
See more data about PBH stock on TipRanks’ Stock Analysis page.